Alison R. Sehgal

Evolutionary divergence of polymorphic HLA residues predicts clinical outcomes after haploidentical stem cell transplantation in patients with AML

Shukaib Arslan, Padma Sri Katikaneni, K M Cooper, Emily M. Geramita et autres

Abstract Introduction: HLA allelic diversity allows for the presentation of broad peptide repertoires to alloreactive donor T-cells and can potentially enhance the graft-versus-leukemia effect (GVL) in allogeneic stem cell transplantation (alloSCT). Several studies have reported HLA evolutionary divergence (HED) as a predictor …

us (code pays fourni par la source)

NCMP-08. Severe Neurotoxicity and Parkinsonism Following BCMA-Directed CAR T-Cell Therapy in Multiple Myeloma: Case Series With Autopsy Findings and Literature Review

Yi Li, Ashley Pritchard, Megan Mantica, Kainat Saleem et autres

Abstract BCMA-directed CAR T-cell therapy has transformed the treatment landscape for relapsed/refractory multiple myeloma (MM). However, delayed neurotoxicity resembling parkinsonism has emerged as a rare but serious complication. We present two patients who developed subacute hypokinetic movement disorders following BCMA CAR T-cell …

us (code pays fourni par la source)

Five-Year Follow-Up Analysis of ZUMA-5: Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Sattva Swarup Neelapu, Julio César Gálvez Chávez, Alison R. Sehgal, Narendranath Epperla et autres

Axicabtagene ciloleucel (axi-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy approved for relapsed/refractory (R/R) follicular lymphoma (FL). Here, we report updated clinical outcomes from ZUMA-5 in 159 enrolled patients with R/R indolent non-Hodgkin lymphoma (iNHL; 127 with FL and …

us, fr (code pays fourni par la source)

Real-world outcomes of cytarabine consolidation in older patients with acute myeloid leukemia.

Dominika Dulak, Emily M. Geramita, Kristine L. Cooper, Kathleen Anne Dorritie et autres

e18535 Background: Acute myeloid leukemia (AML) predominantly affects elderly patients. Standard of care treatment includes induction chemotherapy, followed by consolidation with 4 cycles of high dose cytarabine (HiDAC) at 3gm/m2 with or without allogeneic stem cell transplantation (alloSCT). HiDAC dose was established …

us (code pays fourni par la source)

Lisocabtagene maraleucel for R/R LBCL in patients not intended for HSCT: final results of the phase 2 PILOT study

Alison R. Sehgal, Daanish Hoda, Peter A. Riedell, Nilanjan Ghosh et autres

ABSTRACT: We report final analysis results from the PILOT study of lisocabtagene maraleucel (liso-cel) for patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL). Sixty-one adults with R/R LBCL who had received 1 previous line of therapy and met ≥1 hematopoietic stem cell …

us (code pays fourni par la source)

Prior Exposure to BCMA-Directed Therapy Is Associated with Inferior Outcomes after BCMA CAR-T in Multiple Myeloma – a Single Institution Experience

Kainat Saleem, Joanne Huang, Mounzer Agha, Anastasios Raptis et autres

Introduction Chimeric antigen receptor (CAR)-T therapy, bispecific T-cell engager antibodies (BiTE), and antibody-drug conjugates (ADC) represent revolutionary advances in the treatment of relapsed/refractory (R/R) multiple myeloma (MM). Results from CARTITUTE-2 Cohort C showed reasonable efficacy of BCMA CAR-T after prior exposure to …

us (code pays fourni par la source)

Five-Year Survival of Patients (pts) from Transcend NHL 001 (TRANSCEND) Supports Curative Potential of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Jeremy S. Abramson, Maria Lia Palomba, Leo I. Gordon, Matthew Alexander Lunning et autres

Background: TRANSCEND (NCT02631044) demonstrated high ORR/CR rate with a manageable safety profile in R/R LBCL. At 2-y follow-up, liso-cel showed durable remissions (median duration of response [DOR], 23.1 mo) with no new safety signals (Abramson JS, et al. Blood 2024). In ZUMA-1, …

us (code pays fourni par la source)

5-Year Follow-up Analysis from ZUMA-5: A Phase 2 Trial of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Sattva Swarup Neelapu, Julio César Gálvez Chávez, Alison R. Sehgal, Narendranath Epperla et autres

Introduction: Axi-cel is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy approved for relapsed/refractory (R/R) follicular lymphoma (FL) based on the Phase 2 ZUMA-5 trial in patients (pts) with R/R indolent non-Hodgkin lymphoma (iNHL; FL and marginal zone lymphoma [MZL]). With …

us, fr (code pays fourni par la source)

Comparative efficacy of lisocabtagene maraleucel in the PILOT study versus second-line chemotherapy regimens in the real world

Nilanjan Ghosh, Alison R. Sehgal, Fei‐Fei Liu, Ana Kostić et autres

This study assessed the comparative efficacy of lisocabtagene maraleucel (liso-cel) in the open-label, phase II PILOT study (clinicaltrials.gov NCT03483103) versus conventional second-line (2L) chemotherapy regimens in the real world administered to patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) who …

us, fr (code pays fourni par la source)

EP.02C.01 Investigating the Role of VISTA Immune Checkpoint in Human and Murine Mesothelioma Cell Lines

Alison R. Sehgal, Blake A. Jacobson, H. Zhang, Robert Arthur Kratzke et autres

us (code pays fourni par la source)

P1.02A.01 ADAR1 Regulates Tumorigenesis and Stem Cell Properties in Non-Small Cell Lung Carcinoma

Blake A. Jacobson, Alison R. Sehgal, R. Khadilkar, Robert Arthur Kratzke et autres

EP.14A.05 Targeting ADAR1 for Mesothelioma Therapy

Blake A. Jacobson, Emilia Stoian, R. Khadlikar, Kun Lan et autres

us (code pays fourni par la source)